Could you remind me the number of reps that are in the Cologuard frontline sales channel today and how you're viewing that number for the full year? Obviously, sales reps have been key to getting the penetration of Cologuard to this point, and as you pointed out, I mean that's the recipe for growth. But given what Jeff has said about 50% of the sales reps are still not in person, just wondering how you're looking at that overall frontline number for the year. And then, on Precision Oncology, just wanted to get a sense of how did prostate do in the quarter, and are you seeing any changes in the competitive dynamics out there with another acquisition in this space recently for a prostate competitor?